Prescient Therapeutics Investor Briefing – 17 March
Prescient Therapeutics (ASX: PTX) Webcast Replay
Prescient Therapeutics (ASX: PTX) is focused on developing novel, personalised therapies for a range of cancers. Prescient’s universal CAR-T and targeted therapies seek to improve patient outcomes, whilst also providing new tools for clinicians in combating cancer.
As a part of our ‘The Insiders: Meet the CEOs’ series, CEO Steven Yatomi-Clarke provides valuable insights to the company, its key markets and industry, and future prospects.
Recorded on 17 March 2021 at 12pm (AEDT).
Speak to the Reach Markets team